Channing Global Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.05M Sell
27,792
-15,091
-35% -$696K 0.55% 29
2026
Q2
$2.06M Buy
42,883
+11,698
+38% +$503K 1.06% 20
2026
Q1
$1.15M Sell
31,185
-341
-1% -$16.2K 0.67% 25
2025
Q4
$1.6M Buy
31,526
+7,650
+32% +$391K 1.03% 22
2025
Q3
$1.32M Buy
23,876
+8,648
+57% +$506K 0.92% 23
2025
Q2
$1.05M Buy
15,228
+4,530
+42% +$308K 0.68% 26
2025
Q1
$743K Buy
10,698
+6,581
+160% +$544K 0.51% 28
2024
Q4
$354K Buy
+4,117
New +$445K 0.24% 38
2023
Q3
– Sell
-598
Closed -$48.4K – 49
2023
Q2
$48.4K Sell
598
-604
-50% -$49.3K 0.05% 46
2023
Q1
$95.6K Hold
1,202
– – 0.11% 43
2022
Q4
$81.3K Buy
1,202
+736
+158% +$43.2K 0.09% 41
2022
Q3
$23K Hold
466
– – 0.03% 41
2022
Q2
$26K Hold
466
– – 0.03% 43
2022
Q1
$26K Sell
466
-3,660
-89% -$188K 0.03% 40
2021
Q4
$231K Hold
4,126
– – 0.22% 37

Other funds holding NVO

Channing Global Advisors's NVO Position: Q3 2026 in Review

Channing Global Advisors reduced its Novo Nordisk (NVO) stake by 35% in Q3 2026, selling an estimated $696K and leaving 27,792 shares worth $1.05M. The position accounts for 0.55% of the portfolio, ranked #29.

Channing Global Advisors first reported a position in NVO in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.06M in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Channing Global Advisors held 27,792 shares of Novo Nordisk worth $1.05M as of Q3 2026.
  • Channing Global Advisors sold 15,091 Novo Nordisk shares in Q3 2026, an estimated $696K.
  • Novo Nordisk made up 0.55% of Channing Global Advisors's portfolio in Q3 2026, its #29 holding.
  • Channing Global Advisors first reported a position in Novo Nordisk in Q4 2021 and has held it in 15 quarters since.
  • Channing Global Advisors's Novo Nordisk position peaked at $2.06M in Q2 2026.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Channing Global Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.